Repeatability of AO-SLO (Mona IIa) Technology and Cone Cell Density of Individuals Use Repeated Low-level Red-light Therapy

ConditionMyopia

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age6-55

SponsorRuihua Wei

About this trial

To explore the repeatability of AO-SLO (Mona IIa) technology and the difference of cone cell density between individuals who used or not used repeated low-intensity red light treatment

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

6 - 55 years old, gender not limited; Obtained informed consent.

Disqualifiers

Children with obvious strabismus and amblyopia

With congenital eye disease, such as congenital cataract, congenital retinal disease

Secondary myopia (such as premature retinopathy or other eye diseases in infants and children caused secondary myopia), or myopia combined with systemic syndrome (such as Marfan syndrome)

Had internal eye surgery (such as cataract extraction, intraocular lens implantation, anti-glaucoma surgery, etc.)

Trial design

Design model

Parallel

Treatments tested in this trial

RLRL(Model RS-200-2A, Eyerising; Suzhou Xuanjia Optoelectronic Technology Co., Ltd., Suzhou, China))
Device
use RLRL twice a day

Treatment groups

180 Participants

are divided into 2 treatment groups

Group A: RLRL groupExperimental treatment 1 intervention

Group B: No RLRL GroupNo intervention 0 interventions

Trial outcomes

Primary outcomes

The density of cone cells

Time frame

From enrollment to the end of treatment at 3 weeks

Secondary outcomes

Repeatability of adaptive optics scanning laser ophthalmoscope technology of cone cell density

Time frame

From enrollment to the end of treatment at 3 weeks

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Ruihua Wei

Lead sponsor

Tianjin Medical University Eye Hospital

Sponsor institution

Tianjin Medical University Eye Hospital

Collaborator

Source ClinicalTrials.gov

Apply now